从食后葡萄糖数据中对排放指数的定量估计,在整个耐葡萄糖耐受性谱中进行
Michele Schiavon1, Adrian Vella2, Chiara Dalla Man1
1Department of Information Engineering, University of Padova, Padova, Italy.
概括
我们开发了一种新的方法来评估β细胞功能,仅使用来自持续血糖监测 (CGM) 的葡萄糖数据. 这种排放指数 (DI^G) 准确地估计了非胰岛素治疗个体的β细胞功能,从而实现了现实世界的监测.
科学领域:
- 内分泌学 在内分泌学.
- 代谢性疾病研究研究
- 生物医学工程 生物医学工程
背景情况:
- 贝塔细胞功能对于葡萄糖平衡至关重要,通常用处置指数 (DI) 来衡量.
- 目前的DI评估需要复杂的模型与血葡萄糖,胰岛素和C-数据,限制门诊使用.
- 持续血糖监测 (CGM) 系统为非胰岛素治疗的个人提供了实时DI评估的潜力.
研究的目的:
- 提出并验证一种新方法,仅使用葡萄糖度数据 (DI^G) 来估计排放指数 (DI).
- 评估DI^G与临床和模拟数据集中的参考口腔最小模型 (DI^MM) 的相关性.
- 评估DI^G在监测非胰岛素治疗个体的治疗有效性和葡萄糖耐受性的潜力.
主要方法:
- 利用2型糖尿病和无2型糖尿病患者的混合饮食耐受性测试 (MTT) 的两个临床数据集.
- 使用来自帕多瓦2型糖尿病模拟器的模拟数据集进行进一步验证.
- 仅从葡萄糖数据计算DI^G,并将其与从葡萄糖,胰岛素和C-数据获得的DI^MM进行比较.
主要成果:
- 在临床和模拟数据集中,DI^G与DI^MM有很强的相关性 (R = 0.790.88,P < 0.001).
- 拟议的DI^G方法成功地确定了贝塔细胞功能在访问之间和组间的差异.
- 该方法在不同葡萄糖耐受性和糖尿病状况的个体中表现一致.
结论:
- 该DI^G方法提供了可靠的估计的β细胞功能,仅使用葡萄糖数据.
- 这种方法有助于评估非胰岛素治疗患者的治疗干预和葡萄糖耐受性.
- DI^G有望使用现有CGM技术对现实生活中的β细胞功能进行监测.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
69.4K
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.2K
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Glucose Homeostasis: Regulation of Blood Glucose
2.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.6K
Glucose Absorption Into the Small Intestine
32.4K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.4K
Glucagon-like Receptor Agonists
424
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
424
